Oragenics (OGEN) Common Equity (2010 - 2026)
Oragenics' (OGEN) quarterly Common Equity came in at $6.2 million in Q1 2026, up 4389.69% YoY from $137688.0 in Q1 2025, and down 25.35% on a QoQ basis from $8.3 million in Q4 2025.
Oragenics (OGEN) Common Equity (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Common Equity data on file, last reported at $6.2 million in Q1 2026.
- Quarterly Common Equity rose 4389.69% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 4389.69% YoY) and the FY2025 annual result came in at $8.3 million, up 4008.44% from the prior year.
- Common Equity fell to $6.2 million in Q1 2026, from $8.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $22.0 million in Q1 2022 to a low of -$2.1 million in Q2 2025.
- A 5-year average of $7.4 million and a median of $6.5 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 260.41% — and 2026, when it jumped 4389.69%.
- Tracing OGEN's Common Equity over 5 years: stood at $13.0 million in 2022, then plunged by 75.65% to $3.2 million in 2023, then sank by 106.69% to -$211885.0 in 2024, then soared by 4008.44% to $8.3 million in 2025, then dropped by 25.35% to $6.2 million in 2026.
- The last three Common Equity figures came in at $6.2 million (Q1 2026), $8.3 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 3.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.67 Mn |
| Mar 31, 2026 | 6.18 Mn |
| Dec 31, 2025 | 8.28 Mn |
| Sep 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | -2.13 Mn |
| Mar 31, 2025 | 137,688.00 |
| Dec 31, 2024 | -211,885.00 |
| Sep 30, 2024 | 3.08 Mn |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 3.17 Mn |
| Sep 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 7.26 Mn |
| Mar 31, 2023 | 10.24 Mn |
| Dec 31, 2022 | 13.01 Mn |
| Sep 30, 2022 | 15.27 Mn |
| Jun 30, 2022 | 18.67 Mn |
| Mar 31, 2022 | 21.99 Mn |
| Dec 31, 2021 | 26.49 Mn |
| Sep 30, 2021 | 28.55 Mn |